A double-blind, placebo controlled cross-over study of the effects of the CB2 compound of GW842166 [GW 842166X] in patients with osteoarthritis.

Trial Profile

A double-blind, placebo controlled cross-over study of the effects of the CB2 compound of GW842166 [GW 842166X] in patients with osteoarthritis.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs GW 842166X (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 27 Oct 2008 Actual end date changed from Nov 2007 to Oct 2007 as reported by Clinicaltrials.gov.
    • 12 Oct 2008 Status changed from discontinued to completed as reported by ClinicalTrials.gov.
    • 08 May 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top